search button

VMAT for prostate cancer with 6‑MV and 10‑MV photons: Impact of beam energy on treatment plan quality and model‑based secondary cancer risk estimates

  • Authors:
    • Michalis Mazonakis
    • Stefanos Kachris
    • John Damilakis

  • View Affiliations

  • Published online on: March 5, 2021     https://doi.org/10.3892/mco.2021.2251
  • Article Number: 89
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to examine the effect of the photon beam energy on the volumetric modulated arc therapy (VMAT) plan quality for prostate cancer and on the risk of secondary carcinogenesis. Separate VMAT plans with 6‑MV and 10‑MV photons were created for 11 low‑risk patients with prostate cancer. The prescribed tumor dose was 70 Gy delivered in 28 fractions. The normal tissue integral dose and parameters associated with planning target volume and organs at risk were determined by the treatment planning data. A non‑linear mechanistic model considering the effects of tumor dose fractionation and cell proliferation was employed for estimating the patient‑specific lifetime attributable risk (LAR) for bladder and rectal cancer induction. Data from differential dose‑volume histograms were used for these risk assessments. The mean values of the planning parameters from 6‑MV treatment plans differed by 0.2‑3.4% from those associated with irradiation using 10‑MV photons. The LAR range for developing secondary bladder malignancies varied between 0.041 and 0.129% by the patient under investigation and the beam energy used. The corresponding range for the appearance of rectal malignant diseases was 0.047‑0.153%. The mean percentage difference between the bladder cancer risks from VMAT with 6‑MV and 10‑MV photons was 2.6±2.3%. The corresponding difference for secondary rectal malignancies was 0.7±0.6%. Therefore, VMAT for prostate cancer with both 6‑MV and 10‑MV photons leads to clinically equivalent treatment plans and to similar secondary bladder and rectal cancer risks.
View Figures
View References

Related Articles

Journal Cover

May-2021
Volume 14 Issue 5

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Mazonakis M, Kachris S and Damilakis J: VMAT for prostate cancer with 6‑MV and 10‑MV photons: Impact of beam energy on treatment plan quality and model‑based secondary cancer risk estimates. Mol Clin Oncol 14: 89, 2021.
APA
Mazonakis, M., Kachris, S., & Damilakis, J. (2021). VMAT for prostate cancer with 6‑MV and 10‑MV photons: Impact of beam energy on treatment plan quality and model‑based secondary cancer risk estimates. Molecular and Clinical Oncology, 14, 89. https://doi.org/10.3892/mco.2021.2251
MLA
Mazonakis, M., Kachris, S., Damilakis, J."VMAT for prostate cancer with 6‑MV and 10‑MV photons: Impact of beam energy on treatment plan quality and model‑based secondary cancer risk estimates". Molecular and Clinical Oncology 14.5 (2021): 89.
Chicago
Mazonakis, M., Kachris, S., Damilakis, J."VMAT for prostate cancer with 6‑MV and 10‑MV photons: Impact of beam energy on treatment plan quality and model‑based secondary cancer risk estimates". Molecular and Clinical Oncology 14, no. 5 (2021): 89. https://doi.org/10.3892/mco.2021.2251